HUE042720T2 - Eljárás bizonyos rendellenességek megelõzésére vagy kezelésére IL-4 és/vagy IL-13 saját receptorához történõ kötõdésének gátlása révén - Google Patents

Eljárás bizonyos rendellenességek megelõzésére vagy kezelésére IL-4 és/vagy IL-13 saját receptorához történõ kötõdésének gátlása révén

Info

Publication number: HUE042720T2
Authority: HU; Hungary
Prior art keywords: preventing; methods; inhibiting binding; treating certain; certain disorders
Prior art date: 2011-12-13

Application number

HUE12813295A

Other languages

English (en)

Inventor

Andreas Hohlbaum

Laurent Audoly

Beverly Koller

Original Assignee

Pieris Pharmaceuticals Gmbh

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-12-13

Filing date

2012-12-12

Publication date

2019-07-29

2012-12-12 Application filed by Pieris Pharmaceuticals Gmbh, Astrazeneca Ab filed Critical Pieris Pharmaceuticals Gmbh

2019-07-29 Publication of HUE042720T2 publication Critical patent/HUE042720T2/hu

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Otolaryngology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Marine Sciences & Fisheries (AREA)
Dispersion Chemistry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

HUE12813295A 2011-12-13 2012-12-12 Eljárás bizonyos rendellenességek megelõzésére vagy kezelésére IL-4 és/vagy IL-13 saját receptorához történõ kötõdésének gátlása révén HUE042720T2 (hu)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201161570018P	2011-12-13	2011-12-13

Publications (1)

Publication Number	Publication Date
HUE042720T2 true HUE042720T2 (hu)	2019-07-29

Family

ID=47552959

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HUE12813295A HUE042720T2 (hu)	2011-12-13	2012-12-12	Eljárás bizonyos rendellenességek megelõzésére vagy kezelésére IL-4 és/vagy IL-13 saját receptorához történõ kötõdésének gátlása révén
HUE18197286A HUE054342T2 (hu)	2011-12-13	2012-12-12	Eljárás bizonyos rendellenességek megelõzésére vagy kezelésére render IL-4 és/vagy IL-13 receptorához történõ kötõdésének gátlásával

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
HUE18197286A HUE054342T2 (hu)	2011-12-13	2012-12-12	Eljárás bizonyos rendellenességek megelõzésére vagy kezelésére render IL-4 és/vagy IL-13 receptorához történõ kötõdésének gátlásával

Country Status (13)

Country	Link
US (6)	US9572863B2 (hu)
EP (3)	EP2790719B1 (hu)
JP (5)	JP6163162B2 (hu)
CN (2)	CN103998053B9 (hu)
AU (1)	AU2012350660B2 (hu)
CA (1)	CA2858962C (hu)
DK (2)	DK2790719T3 (hu)
ES (2)	ES2863410T3 (hu)
HU (2)	HUE042720T2 (hu)
PL (2)	PL2790719T3 (hu)
SG (2)	SG10201604566QA (hu)
TR (1)	TR201901826T4 (hu)
WO (1)	WO2013087660A1 (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2580236T3 (pl) *	2010-06-08	2019-09-30	Pieris Pharmaceuticals Gmbh	Muteiny lipokaliny łez wiążące IL-4 R alfa
CA2858962C (en) *	2011-12-13	2023-09-05	Pieris Ag	Compositions of human tear lipocalin muteins and methods of use thereof
CN106573964B (zh) *	2014-05-22	2021-07-16	皮里斯制药有限公司	新型特异性结合多肽及其用途
MX2018000447A (es) *	2015-07-15	2018-08-15	Pieris Pharmaceuticals Gmbh	Novedosas proteinas especificas para lag-3.
CN107474134B (zh) *	2016-06-08	2021-07-27	苏州康乃德生物医药有限公司	用于结合白细胞介素4受体的抗体
US11168119B2 (en)	2017-01-18	2021-11-09	Pieris Pharmaceuticals Gmbh	Lipocalin muteins with binding affinity for LAG-3
AU2018254542B2 (en)	2017-04-21	2022-12-22	Elanco Us Inc.	IL4/IL13 receptor molecule for veterinary use
CN111494625B (zh) *	2018-12-25	2022-06-21	江苏荃信生物医药股份有限公司	用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物
KR20210146934A (ko)	2019-03-29	2021-12-06	아스트라제네카 에이비이	천식 치료를 위한 리포칼린 뮤테인
CN113939307A (zh)	2019-03-29	2022-01-14	皮里斯制药有限公司	脂质运载蛋白突变蛋白的吸入施用
KR20230121785A (ko)	2020-12-18	2023-08-21	아스트라제네카 에이비이	천식 치료용 리포칼린 뮤테인 건조 분말 제형
CN115414467B (zh) *	2022-10-14	2023-06-06	中国人民解放军陆军军医大学第二附属医院	载脂蛋白d在制备治疗脑出血药物中的用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH01215289A (ja)	1988-02-22	1989-08-29	Toa Nenryo Kogyo Kk	遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr)	1988-08-05	1994-03-04	Rhone Poulenc Sante	Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en)	1992-09-23	1998-03-17	Delta Biotechnology Limited	High purity albumin and method of producing
DE4425255A1 (de)	1994-07-16	1996-01-18	Asta Medica Ag	Formulierung zur inhalativen Applikation
US5908621A (en)	1995-11-02	1999-06-01	Schering Corporation	Polyethylene glycol modified interferon therapy
US6446467B1 (en)	1997-07-29	2002-09-10	Physical Optics Corporation	Monolithic glass light shaping diffuser and method for its production
DE19742706B4 (de)	1997-09-26	2013-07-25	Pieris Proteolab Ag	Lipocalinmuteine
ES2251196T3 (es)	1998-06-08	2006-04-16	F. Hoffmann-La Roche Ag	Uso de peg-ifn-alfa y ribavirina para el tratamiento de hepatitis c cronica.
US6403564B1 (en)	1998-10-16	2002-06-11	Schering Corporation	Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de)	1999-06-08	2001-01-11	Arne Skerra	Muteine des Bilin-Bindungsproteins
DE10043509A1 (de)	2000-09-01	2002-03-14	Asta Medica Ag	Feste Peptidzubereitungen für die Inhalation und deren Herstellung
US7211395B2 (en)	2001-03-09	2007-05-01	Dyax Corp.	Serum albumin binding moieties
US7118915B2 (en)	2001-09-27	2006-10-10	Pieris Proteolab Ag	Muteins of apolipoprotein D
WO2003029462A1 (en)	2001-09-27	2003-04-10	Pieris Proteolab Ag	Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US7238661B2 (en) *	2002-05-24	2007-07-03	Agennix, Inc.	Oral lactoferrin in the treatment of respiratory disorders
AU2003275958A1 (en)	2003-08-25	2005-03-10	Pieris Proteolab Ag	Muteins of tear lipocalin
EP1658308A1 (en)	2003-08-25	2006-05-24	Pieris ProteoLab AG	Muteins of a bilin-binding protein with affinity for a given target
RU2389796C2 (ru)	2003-08-29	2010-05-20	Аэровэнс, Инк.	Модифицированный антагонист рецептора il-4 и предназначенный для его получения очищенный полинуклеотид
EP1814988A2 (en)	2004-11-26	2007-08-08	Pieris AG	Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
EP1929073A4 (en)	2005-09-27	2010-03-10	Amunix Inc	PROTEIN MEDICAMENT AND ITS USE
WO2007107563A2 (en)	2006-03-20	2007-09-27	Technische Universität München	Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4
CN105112477A (zh)	2006-08-01	2015-12-02	皮里斯股份公司	泪液脂质运载蛋白的突变蛋白及其获得方法
CA2693785A1 (en) *	2007-07-11	2009-01-15	Aerovance, Inc.	Pharmaceutical polypeptide dry powder aerosol formulation and method of preparation
PL2580236T3 (pl)	2010-06-08	2019-09-30	Pieris Pharmaceuticals Gmbh	Muteiny lipokaliny łez wiążące IL-4 R alfa
CA2858962C (en) *	2011-12-13	2023-09-05	Pieris Ag	Compositions of human tear lipocalin muteins and methods of use thereof

2012
- 2012-12-12 CA CA2858962A patent/CA2858962C/en active Active
- 2012-12-12 CN CN201280061754.7A patent/CN103998053B9/zh active Active
- 2012-12-12 JP JP2014546471A patent/JP6163162B2/ja active Active
- 2012-12-12 WO PCT/EP2012/075146 patent/WO2013087660A1/en active Application Filing
- 2012-12-12 AU AU2012350660A patent/AU2012350660B2/en active Active
- 2012-12-12 ES ES18197286T patent/ES2863410T3/es active Active
- 2012-12-12 DK DK12813295.8T patent/DK2790719T3/en active
- 2012-12-12 US US14/364,449 patent/US9572863B2/en active Active
- 2012-12-12 SG SG10201604566QA patent/SG10201604566QA/en unknown
- 2012-12-12 PL PL12813295T patent/PL2790719T3/pl unknown
- 2012-12-12 SG SG11201402992SA patent/SG11201402992SA/en unknown
- 2012-12-12 EP EP12813295.8A patent/EP2790719B1/en active Active
- 2012-12-12 EP EP21152253.7A patent/EP3842058B1/en active Active
- 2012-12-12 PL PL18197286T patent/PL3453400T3/pl unknown
- 2012-12-12 CN CN201811146540.5A patent/CN109432402B/zh active Active
- 2012-12-12 TR TR2019/01826T patent/TR201901826T4/tr unknown
- 2012-12-12 ES ES12813295T patent/ES2710384T3/es active Active
- 2012-12-12 HU HUE12813295A patent/HUE042720T2/hu unknown
- 2012-12-12 HU HUE18197286A patent/HUE054342T2/hu unknown
- 2012-12-12 DK DK18197286.0T patent/DK3453400T3/da active
- 2012-12-12 EP EP18197286.0A patent/EP3453400B1/en active Active
2016
- 2016-12-02 US US15/367,680 patent/US10016483B2/en active Active
2017
- 2017-03-30 JP JP2017067615A patent/JP6725447B2/ja active Active
2018
- 2018-06-07 US US16/002,704 patent/US10398754B2/en active Active
2019
- 2019-03-28 JP JP2019062186A patent/JP6889201B2/ja active Active
- 2019-07-16 US US16/513,636 patent/US10857202B2/en active Active
2020
- 2020-05-27 JP JP2020092168A patent/JP2020164532A/ja active Pending
- 2020-11-05 US US17/090,571 patent/US11382951B2/en active Active
2022
- 2022-03-25 JP JP2022049676A patent/JP7441589B2/ja active Active
- 2022-06-14 US US17/839,635 patent/US20230021168A1/en active Pending

Also Published As

Publication number	Publication date
US9572863B2 (en)	2017-02-21
CN103998053B9 (zh)	2020-07-21
CA2858962A1 (en)	2013-06-20
JP6725447B2 (ja)	2020-07-15
US20170112900A1 (en)	2017-04-27
DK3453400T3 (da)	2021-04-06
CN103998053A (zh)	2014-08-20
JP2017149733A (ja)	2017-08-31
JP7441589B2 (ja)	2024-03-01
EP2790719B1 (en)	2018-11-21
JP2015505303A (ja)	2015-02-19
JP6889201B2 (ja)	2021-06-18
JP2019116499A (ja)	2019-07-18
PL2790719T3 (pl)	2019-05-31
US20190030121A1 (en)	2019-01-31
JP6163162B2 (ja)	2017-07-12
DK2790719T3 (en)	2019-02-11
US20210145934A1 (en)	2021-05-20
EP3842058A1 (en)	2021-06-30
CN103998053B (zh)	2018-11-02
CN109432402B (zh)	2022-04-29
EP3453400B1 (en)	2021-01-20
AU2012350660B2 (en)	2018-01-25
EP3453400A1 (en)	2019-03-13
US10398754B2 (en)	2019-09-03
EP3842058B1 (en)	2023-08-23
US11382951B2 (en)	2022-07-12
US20200009223A1 (en)	2020-01-09
ES2863410T3 (es)	2021-10-11
SG10201604566QA (en)	2016-07-28
WO2013087660A1 (en)	2013-06-20
SG11201402992SA (en)	2014-07-30
HUE054342T2 (hu)	2021-08-30
PL3453400T3 (pl)	2021-08-09
EP2790719A1 (en)	2014-10-22
AU2012350660A1 (en)	2014-07-03
JP2022084854A (ja)	2022-06-07
CA2858962C (en)	2023-09-05
CN109432402A (zh)	2019-03-08
US20140357548A1 (en)	2014-12-04
US10016483B2 (en)	2018-07-10
ES2710384T3 (es)	2019-04-24
JP2020164532A (ja)	2020-10-08
US10857202B2 (en)	2020-12-08
US20230021168A1 (en)	2023-01-19
TR201901826T4 (tr)	2019-03-21

Publication	Publication Date	Title
HUE042720T2 (hu)	2019-07-29	Eljárás bizonyos rendellenességek megelõzésére vagy kezelésére IL-4 és/vagy IL-13 saját receptorához történõ kötõdésének gátlása révén
IL288048A (en)	2022-01-01	Methods for treating or preventing cholesterol-related disorders
IL260585B (en)	2019-08-29	Preparations and methods for the treatment of diseases related to the retina of the eye
IL226401A0 (en)	2013-07-31	Methods for treating disorders related to @fgfBA
ZA201305783B (en)	2014-04-30	Composition and methods for treating cardiovascular diseases
EP2684167A4 (en)	2014-10-15	COMPOSITIONS AND METHODS USEFUL IN THE TREATMENT OF DISEASES
EP2771030A4 (en)	2015-07-22	COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROTEINOPATHIES
EP2903619A4 (en)	2016-03-16	PHOSPHODIESTERASE INHIBITORS FOR TREATING TASTE AND ODORAT DISORDERS
EP2691529A4 (en)	2014-12-10	METHOD AND COMPOSITIONS FOR TREATING BRAIN DISEASES
IL232710B (en)	2021-12-01	l-serine preparations, methods and uses for the treatment of neurodegenerative diseases and disorders
IL232190A0 (en)	2014-06-30	A method for treating inflammatory diseases by anti-m-csf antibodies
EP2550361A4 (en)	2014-04-30	COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDER
EP2675275A4 (en)	2015-03-11	COMPOSITIONS AND METHODS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS
IL229705A0 (en)	2014-01-30	Methods for the treatment or prevention of neurological diseases
EP2919856A4 (en)	2016-05-04	METHOD AND COMPOSITION FOR THE TREATMENT OF GASTRO-SOPHAGEAL DISORDERS
EP2790711A4 (en)	2015-07-29	METHOD FOR THE USE OF NEURAL STEM CELL COMPOSITIONS FOR THE TREATMENT OF LESIONS OF THE CENTRAL NERVOUS SYSTEM
ZA201309109B (en)	2015-03-25	Methods of treating biomass
EP2709466A4 (en)	2014-11-12	PROCESS FOR TREATING HONEY
IL227703A0 (en)	2013-09-30	Converted Ometic Sulfur Compounds and Methods of Using Them
EP2747785A4 (en)	2015-04-15	METHOD AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASES THROUGH NKG2D INHIBITION
GB201119458D0 (en)	2011-12-21	Compositions for treatment of sleep disorders